Avalon Globocare Corp
NASDAQ:ALBT
Avalon Globocare Corp
Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and the provision of healthcare services. The company is headquartered in Freehold, New Jersey and currently employs 5 full-time employees. The company went IPO on 2016-02-22. The firm is focused on the fields of cellular immunotherapy, including CAR-T/NK; exosome technology (ACTEX), and COVID-19-related vaccine and therapeutics through its subsidiaries. The company operates through two business segments: real property operating segment and medical related consulting services segment. The firm also provides strategic advisory and outsourcing services to facilitate and improve its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Its downstream medical team and facility consists of affiliated hospital networks and experts specialized in hematology, oncology, cellular immunotherapy, hematopoietic stem/progenitor cell transplant, as well as regenerative therapeutics. Its clinical programs include AVA-001, ACTEX, FLASH-CAR, and AVA-Trap.
Avalon GloboCare Corp. is a holding company, which engages in the development of biotechnology and the provision of healthcare services. The company is headquartered in Freehold, New Jersey and currently employs 5 full-time employees. The company went IPO on 2016-02-22. The firm is focused on the fields of cellular immunotherapy, including CAR-T/NK; exosome technology (ACTEX), and COVID-19-related vaccine and therapeutics through its subsidiaries. The company operates through two business segments: real property operating segment and medical related consulting services segment. The firm also provides strategic advisory and outsourcing services to facilitate and improve its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Its downstream medical team and facility consists of affiliated hospital networks and experts specialized in hematology, oncology, cellular immunotherapy, hematopoietic stem/progenitor cell transplant, as well as regenerative therapeutics. Its clinical programs include AVA-001, ACTEX, FLASH-CAR, and AVA-Trap.
